Our upgraded platform utilizes only mg amounts of API to screen amorphous solid dispersion technologies and now has extra screening capabilities for controlled and delayed release formulations. You can now evaluate and address formulation issues early on in the process. This saves crucial time and money.

The majority of current NCEs in pharmaceutical oral delivery pipelines, up to 70%, are BCS II with poor Aqueous Solubility. Another 20% are BCS III or IV with poor permeability.

With these statistics, the odds are high that your current pipeline products are suffering from poor aqueous solubility and/or poor permeability e.g. they have very low oral bioavailability.

Download the fact sheet and let's talk about your next project!

NASH Webinar Coming Soon
Register Today! This online event "Unleashing Innovation: A New Obesogenic NASH Model with High Clinically Translational Power" translates NASH/NAFLD research to clinic with better representative data, faster.
View more
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all